Literature DB >> 28181136

Prognostic value of galactomannan: current evidence for monitoring response to antifungal therapy in patients with invasive aspergillosis.

Laura L Kovanda1,2, Amit V Desai3, William W Hope4.   

Abstract

Galactomannan (GM) is a polysaccharide present in the cell wall of Aspergillus spp. that is released during growth of the organism. It has been successfully used to aide in the diagnosis of invasive aspergillosis allowing for earlier recognition of disease compared to conventional methods. Since its implementation in the clinic as a diagnostic tool, GM has been used in experimental models to measure therapeutic response. Several clinical studies describe the prognostic value of GM. Herein, we review the evidence supporting the utilization of GM antigen as a biomarker to measure response to systemic antifungal therapy.

Entities:  

Keywords:  Antifungal; Aspergillosis; Biomarker; Galactomannan; Prognostic tool

Mesh：

Substances：

Year:  2017        PMID： 28181136     DOI： 10.1007/s10928-017-9509-1

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN： 1567-567X            Impact factor:   2.745


  58 in total

1.  Pathogenesis of Aspergillus fumigatus and the kinetics of galactomannan in an in vitro model of early invasive pulmonary aspergillosis: implications for antifungal therapy.

Authors:  William W Hope; Michael J Kruhlak; Caron A Lyman; Ruta Petraitiene; Vidmantas Petraitis; Andrea Francesconi; Miki Kasai; Diana Mickiene; Tin Sein; Joanne Peter; Amy M Kelaher; Johanna E Hughes; Margaret P Cotton; Catherine J Cotten; John Bacher; Sanjay Tripathi; Louis Bermudez; Timothy K Maugel; Patricia M Zerfas; John R Wingard; George L Drusano; Thomas J Walsh
Journal:  J Infect Dis       Date:  2006-12-21       Impact factor: 5.226

2.  Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America.

Authors:  Thomas J Walsh; Elias J Anaissie; David W Denning; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; Brahm H Segal; William J Steinbach; David A Stevens; Jo-Anne van Burik; John R Wingard; Thomas F Patterson
Journal:  Clin Infect Dis       Date:  2008-02-01       Impact factor: 9.079

Review 3.  Conventional or molecular measurement of Aspergillus load.

Authors:  K V Clemons; D A Stevens
Journal:  Med Mycol       Date:  2008-07-24       Impact factor: 4.076

4.  Efficacy of amphotericin B or amphotericin B-intralipid in combination with caspofungin against experimental aspergillosis.

Authors:  Edward Sionov; Sonia Mendlovic; Esther Segal
Journal:  J Infect       Date:  2005-12-19       Impact factor: 6.072

5.  Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia.

Authors:  Ruta Petraitiene; Vidmantas Petraitis; Andreas H Groll; Tin Sein; Robert L Schaufele; Andrea Francesconi; John Bacher; Nilo A Avila; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

6.  Specificity of a sandwich enzyme-linked immunosorbent assay for detecting Aspergillus galactomannan.

Authors:  C M Swanink; J F Meis; A J Rijs; J P Donnelly; P E Verweij
Journal:  J Clin Microbiol       Date:  1997-01       Impact factor: 5.948

7.  Pharmacodynamics of isavuconazole in experimental invasive pulmonary aspergillosis: implications for clinical breakpoints.

Authors:  Laura L Kovanda; Ruta Petraitiene; Vidmantas Petraitis; Thomas J Walsh; Amit Desai; Peter Bonate; William W Hope
Journal:  J Antimicrob Chemother       Date:  2016-04-15       Impact factor: 5.790

8.  Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B.

Authors:  Thomas J Walsh; Vidmantas Petraitis; Ruta Petraitiene; Aida Field-Ridley; Deanna Sutton; Mahmoud Ghannoum; Tin Sein; Robert Schaufele; Joanne Peter; John Bacher; Heather Casler; Derek Armstrong; Anna Espinel-Ingroff; Michael G Rinaldi; Caron A Lyman
Journal:  J Infect Dis       Date:  2003-07-09       Impact factor: 5.226

9.  Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study.

Authors:  R Herbrecht; J Maertens; L Baila; M Aoun; W Heinz; R Martino; S Schwartz; A J Ullmann; L Meert; M Paesmans; O Marchetti; H Akan; L Ameye; M Shivaprakash; C Viscoli
Journal:  Bone Marrow Transplant       Date:  2010-01-11       Impact factor: 5.483

10.  Earlier diagnosis of invasive fusariosis with Aspergillus serum galactomannan testing.

Authors:  Marcio Nucci; Fabianne Carlesse; Paola Cappellano; Andrea G Varon; Adriana Seber; Marcia Garnica; Simone A Nouér; Arnaldo L Colombo
Journal:  PLoS One       Date:  2014-01-28       Impact factor: 3.240
View more
  12 in total

1.  Pharmacodynamics of Posaconazole in Experimental Invasive Pulmonary Aspergillosis: Utility of Serum Galactomannan as a Dynamic Endpoint of Antifungal Efficacy.

Authors:  Silke Gastine; William Hope; Georg Hempel; Ruta Petraitiene; Vidmantas Petraitis; Diana Mickiene; John Bacher; Thomas J Walsh; Andreas H Groll
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

2.  Combination Therapy with Isavuconazole and Micafungin for Treatment of Experimental Invasive Pulmonary Aspergillosis.

Authors:  Vidmantas Petraitis; Ruta Petraitiene; Matthew W McCarthy; Laura L Kovanda; Myo H Zaw; Kaiser Hussain; Naima Shaikh; Bo Bo W Maung; Navjot K Sekhon; William W Hope; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

3.  Challenges with Utilizing the 1,3-Beta-d-Glucan and Galactomannan Assays To Diagnose Invasive Mold Infections in Immunocompromised Children.

Authors:  Alice J Hsu; Pranita D Tamma; Sean X Zhang
Journal:  J Clin Microbiol       Date:  2021-08-18       Impact factor: 5.948

4.  A Mortality Prediction Rule for Hematology Patients with Invasive Aspergillosis Based on Serum Galactomannan Kinetics.

Authors:  Toine Mercier; Joachim Wera; Louis Y A Chai; Katrien Lagrou; Johan Maertens
Journal:  J Clin Med       Date:  2020-02-24       Impact factor: 4.241

5.  Invasive aspergillosis in solid organ transplant patients: diagnosis, prophylaxis, treatment, and assessment of response.

Authors:  Dionysios Neofytos; Carolina Garcia-Vidal; Frédéric Lamoth; Christoph Lichtenstern; Alessandro Perrella; Jörg Janne Vehreschild
Journal:  BMC Infect Dis       Date:  2021-03-24       Impact factor: 3.090

Review 6.  The Evolving Landscape of Fungal Diagnostics, Current and Emerging Microbiological Approaches.

Authors:  Zoe Freeman Weiss; Armando Leon; Sophia Koo
Journal:  J Fungi (Basel)       Date:  2021-02-09

7.  Antibody-guided in vivo imaging of Aspergillus fumigatus lung infections during antifungal azole treatment.

Authors:  Sophie Henneberg; Anja Hasenberg; Andreas Maurer; Franziska Neumann; Lea Bornemann; Irene Gonzalez-Menendez; Andreas Kraus; Mike Hasenberg; Christopher R Thornton; Bernd J Pichler; Matthias Gunzer; Nicolas Beziere
Journal:  Nat Commun       Date:  2021-03-17       Impact factor: 14.919

Review 8.  Diagnostic Approaches for Invasive Aspergillosis-Specific Considerations in the Pediatric Population.

Authors:  Thomas Lehrnbecher; Angela Hassler; Andreas H Groll; Konrad Bochennek
Journal:  Front Microbiol       Date:  2018-03-26       Impact factor: 5.640

9.  Future challenges and chances in the diagnosis and management of invasive mould infections in cancer patients.

Authors:  Jörg Janne Vehreschild; Philipp Koehler; Frédéric Lamoth; Juergen Prattes; Christina Rieger; Bart J A Rijnders; Daniel Teschner
Journal:  Med Mycol       Date:  2021-01-04       Impact factor: 4.076

10.  When to change treatment of acute invasive aspergillosis: an expert viewpoint.

Authors:  Monica A Slavin; Yee-Chun Chen; Catherine Cordonnier; Oliver A Cornely; Manuel Cuenca-Estrella; J Peter Donnelly; Andreas H Groll; Olivier Lortholary; Francisco M Marty; Marcio Nucci; John H Rex; Bart J A Rijnders; George R Thompson; Paul E Verweij; P Lewis White; Ruth Hargreaves; Emma Harvey; Johan A Maertens
Journal:  J Antimicrob Chemother       Date:  2021-12-24       Impact factor: 5.790
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.